Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage: A randomized controlled trial

Obstetrics and Gynecology

Volumn 121, Issue 1, 2013, Pages 78-86

  Elgindy, Eman A ^a   El Haieg, Dahlia O ^a   Khorshid, Ola M ^a   Ismail, Eman I ^a   Abdelgawad, Mohamed ^a   Sallam, Hassan N ^a   Abou Setta, Ahmed M ^a  

^a ZAGAZIG UNIVERSITY   (Egypt)

Author keywords

[No Author keywords available]

Indexed keywords

CETRORELIX; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTRADIOL; FLUOROURACIL; FOLLITROPIN; GONADOTROPIN; LUTEINIZING HORMONE; MUELLERIAN INHIBITING FACTOR; TRIPTORELIN;

ADULT; AMENORRHEA; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CHEMOTHERAPY INDUCED AMENORRHEA; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; EARLY INTERVENTION; EGYPT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THERAPY DELAY; TRANSVAGINAL ECHOGRAPHY; TREATMENT OUTCOME; UNIVERSITY HOSPITAL;

EID: 84872104475     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0b013e31827374e2     Document Type: Article

References (28)

1. Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Semin Oncol 2009;36:237-49.
2. Anders CK, Hsu DS, Broadwater G, Acharya CR, Foekens JA, Zhang Y, et al. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol 2008;26:3324-30.
3. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-83.
4. Carlson RW, Anderson BO, Burstein HJ, Carter WB, Edge SB, Farrar WB, et al. Invasive breast cancer. J Natl Compr Canc Netw 2007;5:246-312.
5. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-62.
6. Sutcliffe SB. Cytotoxic chemotherapy and gonadal function in patients with Hodgkin's disease. Facts and thoughts. JAMA 1979;242:1898-9.
7. Wallace WH, Shalet SM, Tetlow LJ, Morris-Jones PH. Ovarian function following the treatment of childhood acute lymphoblastic leukaemia. Med Pediatr Oncol 1993;21:333-9.
8. Bedaiwy MA, Abou-Setta AM, Desai N, Hurd W, Starks D, El- Nashar SA, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011;95:906-14 e1-4.
9. Kim SS, Lee JR, Jee BC, et al. Use of hormonal protection for chemotherapy-induced gonadotoxicity. Clin Obstet Gynecol 2010;53:740-52.
10. von Wolff M, Kämmerer U, Kollmann Z, Santi A, Dietl J, Frambach T. Combination of gonadotropin-releasing hormone (GnRH) agonists with GnRH antagonists before chemotherapy reduce but does not completely prevent a follicle-stimulating hormone flare-up. Fertil Steril 2011;95:452-4.
11. Mardesic T, Snajderova M, Sramkova L, Keslova P, Sedlacek P, Stary J. Protocol combining GnRH agonists and GnRH antagonists for rapid suppression and prevention of gonadal damage during cytotoxic therapy. Eur J Gynaecol Oncol 2004;25:90-2.
12. Roth CL, Brendel L, Ruckert C, Hartmann K. Antagonistic and agonistic GnRH analogue treatment of precocious puberty: tracking gonadotropin concentrations in urine. Horm Res 2005;63:257-62.
13. Potolog-Nahari C, Fishman A, Cohen I. Protection of ovarian function and fertility using a combination of gonadotropinreleasing hormone (GnRH) agonist and GnRH antagonist during cancer treatment in young females. Gynecol Endocrinol 2007;23:290-4.
14. Danforth DR, Arbogast LK, Friedman CI. Acute depletion of murine primordial follicle reserve by gonadotropin-releasing hormone antagonists. Fertil Steril 2005;83:1333-8.
15. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropinreleasing hormone agonists for prevention of chemotherapyinduced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7.
16. Blumenfeld Z. ZORO Study: discrepancy between the conclusion and the results. J Clin Oncol 2011;29:1.
17. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-29.
18. World Health Organization. Research on the menopause.Technical Report Series 670. Geneva (Switzerland): WHO; 1991.
19. Fornier MN, Modi S, Panageas KS, Norton L, Hudis C. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane. Cancer 2005;104:1575-9.
20. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al. Effect of luteinizing hormonereleasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol 2011;29:2334-41.
21. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropinreleasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-8.
22. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapyinduced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-76.
23. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. The Cochrane Database of Systematic Reviews 2011, Issue11. Art. No.: CD008018. DOI: 10.1002/14651858.CD008018. pub2.
24. Oktay K, Sonmezer M. Questioning GnRH analogs for gonadal protection in cancer patients. Fertil Steril 2009;92:e32.
25. Balkenende E, Dahhan T, van der Veen F, Goddijn M. Comment on GnRH analogue cotreatment with chemotherapy for preservation of ovarian function. Fertil Steril 2011;96:e155-6.
26. Gracia CR, Sammel MD, Freeman E, Prewitt M, Carlson C, Ray A, et al. Impact of cancer therapies on ovarian reserve. Fertil Steril 2012;97:134-40e1.
27. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12:1044-54.
28. Oktay K, Briggs D, Gosden RG. Ontogeny of follicle-stimulating hormone receptor gene expression in isolated human ovarian follicles. J Clin Endocrinol Metab 1997;82:3748-51.